The clinical logic behind Mabwell’s ESMO oral slot is sharper than the announcement suggests: the Phase 2 study of bulumtatug fuvedotin (9MW2821) specifically enrolled patients with locally advanced or metastatic triple-negative breast cancer who had already progressed on a topoisomerase I inhibitor-based ADC. That enrollment criterion defines a population with narrowing options, because sacituzumab govitecan, a Topo I-payload ADC, has become deeply embedded in the TNBC treatment sequence after FDA approval for first-line TNBC in June 2026 and prior regulatory clearances in China and Europe. A Nectin-4-directed agent with a distinct payload mechanism is positioned to occupy exactly the post-Topo I slot where options shrink fast.
The biological premise holds up. Nectin-4 is highly expressed in roughly 58% of TNBC tumors, which means target availability is not a theoretical concern in this histology. Crucially, Nectin-4 expression is independent of the molecular drivers that make TNBC heterogeneous, so the target selection rationale does not collapse when you shift from HER2-low or BRCA-mutated subgroups into the broader refractory population. Mabwell’s Phase 2 design implicitly acknowledges this: the trial is not chasing a biomarker-selected fragment of TNBC; it is testing a defined treatment-history criterion as the enrollment gate.
An oral presentation at ESMO rather than a poster is a meaningful signal about data maturity and abstract review committee confidence. Professor Zhang Jian of Fudan University Shanghai Cancer Center is presenting, which anchors this in one of China’s highest-volume breast cancer programs and gives the dataset international credibility ahead of any regulatory conversations. The session on October 26 sits inside the advanced breast cancer block, meaning Mabwell will be presenting directly alongside competitive data from more established programs. That competitive proximity at a major congress is a feature, not a risk, if the response rates and durability in a Topo I-pretreated cohort are compelling.
The single number worth watching when the abstract goes public is objective response rate in confirmed Topo I-pretreated patients, because that figure will determine whether bulumtatug fuvedotin is a viable second ADC in sequence or simply an academic exercise in target biology.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
